Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBT Margin (2016 - 2025)

Historic EBT Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 11.21%.

  • Amphastar Pharmaceuticals' EBT Margin fell 137200.0% to 11.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.51%, marking a year-over-year decrease of 78200.0%. This contributed to the annual value of 26.66% for FY2024, which is 15700.0% down from last year.
  • Amphastar Pharmaceuticals' EBT Margin amounted to 11.21% in Q3 2025, which was down 137200.0% from 22.55% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' EBT Margin's 5-year high stood at 38.83% during Q4 2022, with a 5-year trough of 4.96% in Q1 2021.
  • Moreover, its 5-year median value for EBT Margin was 23.97% (2023), whereas its average is 23.42%.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBT Margin skyrocketed by 295000bps in 2021, and later crashed by -147400bps in 2022.
  • Amphastar Pharmaceuticals' EBT Margin (Quarter) stood at 22.47% in 2021, then soared by 73bps to 38.83% in 2022, then fell by -25bps to 29.14% in 2023, then dropped by -9bps to 26.47% in 2024, then tumbled by -58bps to 11.21% in 2025.
  • Its last three reported values are 11.21% in Q3 2025, 22.55% for Q2 2025, and 18.1% during Q1 2025.